	US 11,957,680 B2
	Pyruvate kinase activators for use in treating blood disorders
Giovanni Cianchetta, Boxford, MA (US); Tao Liu, Wellesley, MA (US); Anil Kumar Padyana, Lexington, MA (US); Zhihua Sui, Audubon, PA (US); Zhenwei Cai, Shanghai (CN); Dawei Cui, Shanghai (CN); and Jingjing Ji, Shanghai (CN)
Assigned to Agios Pharmaceuticals, Inc., Cambridge, MA (US)
Filed by Agios Pharmaceuticals, Inc., Cambridge, MA (US)
Filed on May 16, 2022, as Appl. No. 17/744,806.
Application 17/744,806 is a continuation of application No. 16/639,075, granted, now 11,364,240, previously published as PCT/US2018/000127, filed on Aug. 15, 2018.
Claims priority of provisional application 62/673,533, filed on May 18, 2018.
Claims priority of provisional application 62/673,526, filed on May 18, 2018.
Claims priority of application No. PCT/CN2017/097496 (WO), filed on Aug. 15, 2017.
Prior Publication US 2022/0395503 A1, Dec. 15, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/5025 (2006.01); A61K 31/506 (2006.01); A61K 31/519 (2006.01); C07D 241/36 (2006.01); C07D 513/14 (2006.01); A61K 45/06 (2006.01)

CPC A61K 31/5025 (2013.01) [A61K 31/506 (2013.01); A61K 31/519 (2013.01); C07D 241/36 (2013.01); C07D 513/14 (2013.01); A61K 45/06 (2013.01)]

14 Claims

1. A compound having a structural formula selected from:

or a pharmaceutically acceptable salt thereof.